Taken as a whole, our study demonstrates that the combined use of Carboplatin, Paclitaxel and MSLN inhibition may synergistically inhibit breast cancer liver metastasis, offering therapeutic benefit to TNBC patients with liver metastasis. The gene discussed is MSLN; the disease is breast carcinoma.